Edesa Biotech is a biopharmaceutical company focusing on the development of clinical-stage drugs to treat inflammatory and immune-related diseases with unmet medical needs. The company's key drugs in development include EB05 and EB01, both of which are in different stages of clinical study. Edesa was founded in 2015 and is based in Markham, Canada, and has a license agreement with NovImmune SA for the development of monoclonal antibodies.